Diamond Hill Capital's PFE Position Overview
Diamond Hill Capital (via Diamond Hill Capital Management INC) currently holds 9.44 M shares of Pfizer Inc. (PFE) worth $235.04 M, representing 1.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Diamond Hill Capital has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2023, adding 5.19 M shares. Largest reduction occurred in Q3 2025, reducing 6.74 M shares.
Analysis based on 13F filings available since 2013 Q2
Diamond Hill Capital's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Diamond Hill Capital
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1.48 M | Reduce 13.59% | 9.44 M | $24.90 |
| Q3 2025 | -6.74 M | Reduce 38.16% | 10.92 M | $25.48 |
| Q2 2025 | -952,171 | Reduce 5.11% | 17.66 M | $24.24 |
| Q1 2025 | -6,832 | Reduce 0.04% | 18.62 M | $25.34 |
| Q4 2024 | +2.07 M | Add 12.50% | 18.62 M | $26.53 |
| Q3 2024 | +658,420 | Add 4.14% | 16.55 M | $28.94 |
| Q2 2024 | -210,435 | Reduce 1.31% | 15.9 M | $27.98 |
| Q1 2024 | +4.31 M | Add 36.51% | 16.11 M | $27.75 |
| Q4 2023 | +5.19 M | Add 78.67% | 11.8 M | $28.79 |
| Q3 2023 | -296,444 | Reduce 4.30% | 6.6 M | $33.17 |
| Q2 2023 | +131,305 | Add 1.94% | 6.9 M | $36.68 |
| Q1 2023 | -30,443 | Reduce 0.45% | 6.77 M | $40.80 |
| Q4 2022 | -1.2 M | Reduce 14.96% | 6.8 M | $51.24 |
| Q3 2022 | -1.12 M | Reduce 12.26% | 8 M | $43.76 |
| Q2 2022 | -293,502 | Reduce 3.12% | 9.11 M | $52.43 |
| Q1 2022 | -413,679 | Reduce 4.21% | 9.41 M | $51.77 |
| Q4 2021 | -825,746 | Reduce 7.76% | 9.82 M | $59.05 |
| Q3 2021 | -1.04 M | Reduce 8.86% | 10.65 M | $43.01 |
| Q2 2021 | +438,427 | Add 3.90% | 11.68 M | $39.16 |
| Q1 2021 | +2.06 M | Add 22.49% | 11.24 M | $36.23 |
| Q4 2020 | +467,368 | Add 5.37% | 9.18 M | $36.81 |
| Q3 2020 | -88,396 | Reduce 1.00% | 8.71 M | $36.70 |
| Q2 2020 | +63,223 | Add 0.72% | 8.8 M | $32.70 |
| Q1 2020 | +606,061 | Add 7.45% | 8.74 M | $32.64 |
| Q4 2019 | -118,232 | Reduce 1.43% | 8.13 M | $39.18 |
| Q3 2019 | +546,541 | Add 7.10% | 8.25 M | $35.93 |
| Q2 2019 | +114,064 | Add 1.50% | 7.7 M | $43.32 |
| Q1 2019 | +284,683 | Add 3.90% | 7.59 M | $42.47 |
| Q4 2018 | -745,581 | Reduce 9.26% | 7.3 M | $43.65 |
| Q3 2018 | -507,041 | Reduce 5.93% | 8.05 M | $44.07 |
| Q2 2018 | -951,533 | Reduce 10.01% | 8.56 M | $36.28 |
| Q1 2018 | -1.4 M | Reduce 12.85% | 9.51 M | $35.49 |
| Q4 2017 | -219,493 | Reduce 1.97% | 10.91 M | $36.22 |
| Q3 2017 | -203,127 | Reduce 1.79% | 11.13 M | $35.70 |
| Q2 2017 | -1.03 M | Reduce 8.31% | 11.33 M | $33.59 |
| Q1 2017 | -598,959 | Reduce 4.62% | 12.36 M | $34.21 |
| Q4 2016 | +1.1 M | Add 9.28% | 12.96 M | $32.48 |
| Q3 2016 | +209,704 | Add 1.80% | 11.86 M | $33.87 |
| Q2 2016 | +400,968 | Add 3.57% | 11.65 M | $35.21 |
| Q1 2016 | +524,230 | Add 4.89% | 11.25 M | $29.64 |
| Q4 2015 | +340,439 | Add 3.28% | 10.72 M | $32.28 |
| Q3 2015 | +146,004 | Add 1.43% | 10.38 M | $31.41 |
| Q2 2015 | -197,433 | Reduce 1.89% | 10.23 M | $33.53 |
| Q1 2015 | -180,534 | Reduce 1.70% | 10.43 M | $34.79 |
| Q4 2014 | +417,118 | Add 4.09% | 10.61 M | $31.15 |
| Q3 2014 | +816,955 | Add 8.71% | 10.2 M | $29.57 |
| Q2 2014 | +587,875 | Add 6.69% | 9.38 M | $29.68 |
| Q1 2014 | +451,874 | Add 5.42% | 8.79 M | $32.12 |
| Q4 2013 | +347,060 | Add 4.34% | 8.34 M | $30.63 |
| Q3 2013 | +40,561 | Add 0.51% | 7.99 M | $28.71 |
| Q2 2013 | +7.95 M | Add 0.00% | 7.95 M | $28.01 |
Diamond Hill Capital's Pfizer Investment FAQs
Diamond Hill Capital first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 7,951,442 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital has held Pfizer Inc. (PFE) for 51 quarters since Q2 2013.
Diamond Hill Capital's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 7,951,442 shares worth $222.72 M.
According to the latest 13F filing for Q4 2025, Diamond Hill Capital's firm, Diamond Hill Capital Management INC, owns 9,439,267 shares of Pfizer Inc. (PFE), valued at approximately $235.04 M.
As of the Q4 2025 filing, Pfizer Inc. (PFE) represents approximately 1.20% of Diamond Hill Capital's publicly disclosed stock portfolio, making it one of their key holdings.
Diamond Hill Capital's peak holding in Pfizer Inc. (PFE) was 18,623,356 shares, as reported at the end of Q4 2024.